Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  British American Tobacco    BATS   GB0002875804

My previous session
Most popular
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets

British American Tobacco : Switching from smoking to glo significantly reduces exposure to toxicants

share with twitter share with LinkedIn share with facebook
share via e-mail
03/08/2018 | 06:13pm CEST

By a News Reporter-Staff News Editor at Clinical Trials Week -- A clinical study conducted by scientists at British American Tobacco have revealed that when smokers switch completely from cigarettes to glo, their exposure to certain cigarette smoke toxicants is significantly reduced, in some cases to levels comparable to those seen in smokers who quit smoking completely (see also R&D at British American Tobacco).

These results add to evidence suggesting that glo may have the potential to be substantially reduced risk compared to smoking conventional cigarettes.

glo is a tobacco heating product (THP) designed to heat rather than burn tobacco. This means it does not produce smoke and certain toxicants associated with tobacco combustion are substantially reduced. Previous studies revealed toxicant levels in the heated tobacco vapour from glo to be around 90-95% less than in cigarette smoke.

'Products like glo are very new and consumers and regulators alike understandably want as much information as possible about them. Understanding how vapour from glo compares to cigarette smoke is, therefore, a core component of our scientific research,' said Dr James Murphy, Head of Reduced Risk Substantiation at British American Tobacco. 'Clinical studies, which are studies involving real people, are an extremely important component of that,' he said.

Because glo vapour has lower levels of toxicants than cigarette smoke, it should in principle expose consumers to much less toxicants. The results of this study indicate that this is indeed the case. The results are presented today at the annual conference of the Society for Nicotine and Tobacco Research in Baltimore, Maryland, USA.

This clinical study was conducted in Japan because THPs like glo are popular there. One hundred and eighty people participated in the study, which was conducted over a period of eight days in a clinic. They were all smokers for at least three years prior to enrolment.

For the first two days, study participants continued to smoke as normal and their urine was collected to measure levels of chemicals. Blood and breath were also collected for analysis.

For the next five days, participants were randomly allocated to either continue smoking, switch to using a THP or quit smoking. Urine, blood and breath samples were again collected for analysis.

Exposure to certain smoke toxicants was determined by measuring the levels of certain chemicals in the urine. These could be the toxicants themselves or their metabolites - which is what the body breaks it down into - called biomarkers of exposure. Toxicants measured included those identified by the World Health Organisation as being of concern in cigarette smoke.

The results show that the concentration of certain chemicals in the urine was reduced in smokers who switched to glo. In some cases, these reductions were the same as those in smokers who quit (Figure 1). This suggests that smokers who switched to glo were exposed to less toxicants - in some cases, their exposure was the same as smokers who quit altogether.

'These results are very encouraging,' explains Murphy. 'The next step will be to determine whether this reduction in exposure translates to a reduced biological effect, and in turn a reduction in adverse health effects for those smokers who switch completely to glo,' he said.

Future clinical studies will test for markers of biological effect, like cholesterol levels or heart rate (i.e. measurements that give an indication of general health). A reduction in biomarkers of biological effect could suggest that a reduction in exposure is having a positive impact on reducing the adverse health risks of smokers who switch completely.

'The results of one test are important,' said Murphy, 'but it is the combination of the results of many different tests that start to give us a real feel for the bigger picture and the potential for glo to be reduced risk compared to a conventional cigarette.'

Keywords for this news article include: Smoking, Chemicals, Clinical Research, Health and Medicine, Risk and Prevention, Clinical Trials and Studies, R&D at British American Tobacco.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2018, NewsRx LLC

(c) 2018 NewsRx LLC, source Health Newsletters

share with twitter share with LinkedIn share with facebook
share via e-mail
09/20BRITISH AMERICAN TOBACCO : Patent Issued for Feed Unit (USPTO 10,071,866)
09/20BRITISH AMERICAN TOBACCO : Council’s vaping project with British American ..
09/20BRITISH AMERICAN TOBACCO : British American Tobacco only tobacco company feature..
09/20BRITISH AMERICAN TOBACCO : British American Tobacco announces CEO's intention to..
09/20NICANDRO DURANTE : British American Tobacco CEO Nicandro Durante to Retire
09/20British American Tobacco CEO to Step Down in Next Year -Sky News
09/20BRITISH AMERICAN TOBACCO : boss to exit within a year
09/20BRITISH AMERICAN TOBACCO : has candidate to replace retiring chief exec
09/20BRITISH AMERICAN TOBACCO : has candidate to replace retiring chief exec
More news
News from SeekingAlpha
09/22U.S. teen e-cigarette use threatens market 
09/22STOCKS TO WATCH : Calling Up Animal Spirits 
09/21Philip Morris to pass on grass 
09/20British American Tobacco's CEO to retire in April 2019 
09/16INTERACTIVE BROKERS - FROM GOVERNMEN : Tobacco Stocks Face Mounting Challenges 
Financials (GBP)
Sales 2018 24 527 M
EBIT 2018 10 397 M
Net income 2018 6 285 M
Debt 2018 44 100 M
Yield 2018 5,48%
P/E ratio 2018 12,56
P/E ratio 2019 11,34
EV / Sales 2018 5,18x
EV / Sales 2019 4,86x
Capitalization 82 965 M
Duration : Period :
British American Tobacco Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BRITISH AMERICAN TOBACCO
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 46,9  GBP
Spread / Average Target 30%
EPS Revisions
Nicandro Durante Chief Executive Officer & Executive Director
Richard George William Burrows Chairman
Alan Davy Director-Group Operations
John Benedict Stevens Executive Director & Finance Director
David O'Reilly Group Scientific Director & Director-Research
Sector and Competitors
1st jan.Capitalization (M$)
IMPERIAL BRANDS-16.05%33 125
SWEDISH MATCH41.62%9 164
ESSENTRA-21.78%1 419
PHILIP MORRIS CR, A.S.--.--%1 306